Sugi Predict

Sugi Predict / Compounds / SCHEMBL402494

SCHEMBL402494

SCHEMBL402494

NC(=O)CC[C@H](N)C(=O)OC(=O)Cc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 3/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ ALDH1A1 P00352 1/20 0.46
▸ PAM P19021 1/20 0.45
▸ TSHR P16473 1/20 0.44
▸ ALOX15 P16050 1/20 0.43
▸ BLM P54132 1/20 0.43
▸ PMP22 Q01453 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ LTA4H P09960 3/20 0.40
▸ SLC7A5 Q01650 2/20 0.40
▸ ALPI P09923 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ XIAP P98170 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ HTT P42858 1/20 0.39
▸ SLC15A1 P46059 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3340704 0.99 L3MBTL1 (0.45) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL28376925 0.86 ALDH1A1 (0.44) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL17458666 0.85 ALDH1A1 (0.49) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL4810846 0.84 ALPI (0.53) ALOX15BLMPMP22KMT2ALTA4H
SCHEMBL1702340 0.82 ALDH1A1 (0.46) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL15532005 0.81 SLC7A5 (0.58) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL8740769 0.81 ALDH1A1 (0.51) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL28231845 0.81 MMP2 (0.50) L3MBTL1MAPK1ALDH1A1PAMTSHR
SCHEMBL6672089 0.81 LTA4H (0.44) ALDH1A1TSHRALOX15BLMPMP22
SCHEMBL4989084 0.80 LTA4H (0.48) L3MBTL1MAPK1ALDH1A1ALOX15BLM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 199 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113009122-B Methods and systems for determining the risk of autism spectrum disorder 美国控股实验室公司 2025-01-17 — — CN claimed
WO-2024243289-A2 GUT MICROBE DERIVED AROMATIC AMINO ACID METABOLITES FOR DETECTION AND TREATMENT OF DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2024-11-28 — — WO claimed
CN-110088615-B Mass spectrometry assay for detection and quantification of renal function metabolites 梅塔博隆股份有限公司 2023-08-22 — — CN claimed
US-20230091848-A1 DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS THE CLEVELAND CLINIC FOUNDATION 2023-03-23 — — US claimed
EP-4100541-A1 DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS The Cleveland Clinic Foundation (US) 2022-12-14 — — EP claimed
CN-111024843-B Combined marker for diagnosing Parkinson's disease and detection kit 大连医科大学附属第一医院 2022-06-21 — — CN claimed
CN-113970606-B Metabolic markers for diagnosing attention deficit hyperactivity disorder syndrome in urine of children 首都医科大学附属北京儿童医院 2022-06-14 — — CN claimed
WO-2021158720-A1 DISEASE DETECTION AND TREATMENT BASED ON PHENYLACETYL GLUTAMINE LEVELS THE CLEVELAND CLINIC FOUNDATION (US) 2021-08-12 — — WO claimed
CN-111406216-A Compounds, reagents and uses thereof 麦特博隆股份有限公司 2020-07-10 — — CN claimed
CN-111024843-A Combined marker for diagnosing Parkinson's disease and detection kit 大连医科大学附属第一医院 2020-04-17 — — CN claimed
US-8642012-B2 Methods of treatment using ammonia-scavenging drugs HYPERION THERAPEUTICS, INC. (US) 2014-02-04 — — US claimed
US-20130210914-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS HYPERION THERAPEUTICS, INC. (US) 2013-08-15 — — US claimed
US-20120022157-A1 DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS UCYCLYD PHARMA, INC (US) 2012-01-26 — — US claimed
EP-2338050-A1 DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS Ucyclyd Pharma, Inc. (US) 2011-06-29 — — EP claimed
EP-2330892-A1 METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS Ucyclyd Pharma, Inc. (US) 2011-06-15 — — EP claimed
WO-2010025303-A9 DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS HYPERION THERAPEUTICS (US) 2010-06-24 — — WO claimed
WO-2010025303-A1 DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS HYPERION THERAPEUTICS (US) 2010-03-04 — — WO claimed
US-20100008859-A1 METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS HORIZON THERAPEUTICS U.S. HOLDING LLC 2010-01-14 — — US claimed
WO-2009134460-A1 METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS HYPERION THERAPEUTICS (US) 2009-11-05 — — WO claimed
EP-0069232-A2 Pharmaceutical composition comprising phenyl acetyl glutamine,a combination of this compound with phenylacetic acid or 3-(phenylacetylamino)piperidine-2,6-dione,a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylamino)piperidine-2,6-dione BURZYNSKI, Stanislaw R. (US) 1983-01-12 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022157-A1 DOSING AND MONITORING PATIENTS ON NITROGEN-SCAVENGING DRUGS PLPBP, GLS, NPPA L3MBTL1 1820/4885MAPK1 3115/4885ALDH1A1 1171/4885
US-20100008859-A1 METHODS OF TREATMENT USING AMMONIA-SCAVENGING DRUGS OAT, SLC1A5, GLS L3MBTL1 2878/4885MAPK1 3981/4885ALDH1A1 765/4885
US-20130210914-A1 METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS OAT, NPR1, CPS1 L3MBTL1 1571/4885MAPK1 4297/4885ALDH1A1 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.